```json
{
"content": [
{
"type": "paragraph",
"content": "Psoriatic Arthritis (PsA) Treatment Market encompasses therapeutic solutions for managing this chronic autoimmune condition, which affects both joints and skin. The PsA treatment market size reached $4.8 billion in 2023, with a projected CAGR of 7.5% from 2026 to 2033, driven by rising disease prevalence, advancements in biologics and biosimilars, and favorable regulatory support. The market forecast underscores robust industry expansion, particularly in biologics and small molecule therapies, positioning PsA as a high-growth segment within rheumatology care."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Biologics", "Small Molecules", "Others"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[20, 22, 25, 28, 30, 33, 36, 40, 44, 48, 52, 56, 60], // Biologics
[10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22], // Small Molecules
[5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6] // Others
]
}
},
{
"type": "paragraph",
"content": "Key forces shaping the PsA treatment landscape include innovation in targeted therapies (e.g., IL-17/IL-23 inhibitors) and the approval of biosimilars reducing treatment costs. North America remains the largest market, led by the U.S., while Asia-Pacific is the fastest-growing region due to rising awareness and expanding healthcare infrastructure. Competitive intensity is elevating as pharmaceutical players prioritize R&D to address unmet needs in disease subtypes and patient adherence. Strategic collaborations and pipeline advancements are central to capturing market share in this dynamic sector."
}
]
}
```
